Development of a gradient elution high-performance liquid chromatography assay with ultraviolet detection for the determination in plasma of the anticancer peptide [Arg6, d-Trp7,9, mePhe8]-substance P (6–11) (antagonist G), its major metabolites and a C-terminal pyrene-labelled conjugate

On‐line coupling of size exclusion and capillary zone electrophoresis via a reversed‐phase C18 trapping column for the analysis of structurally related enkephalins in cerebrospinal fluid

“…The results show that it is possible to analyze these closely structural related peptides directly in biological matrices such as CSF, indicating the large selectivity of this rapid multidimensional system. The CLOQ of the enkephalins in this system is 2.5 mg/mL, which is comparable to the CLOQ in the earlier presented SEC-LC system [25] and sufficient for the analysis of exogenous peptides used as drugs [30][31][32]. Both CLOQ values cannot be increased by increasing the injection volume higher than 10 mL.…”

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry

“…structural analogs [52] or protein-rich solutions, like plasma or serum albumin [35,49,50,[53][54][55][56][57][58]. Addition of organic solvents [34,[46][47][48]59], acids [34,47] or salts [23,41,60] has also been mentioned to reduce adsorptive losses, mainly by improving the peptide's solubility. The use of surfactants to reduce adsorptive losses has been frequently reported [25,33,47,61], but these compounds are not compatible with MS measurements and have not been used in quantitative LC-MS assays [46].…”

“…Other bioanalytical procedures, specifically used in the bioanalysis of peptide therapeutics are liquid chromatography (LC) combined with ultraviolet (UV) [22][23][24][25][26][27][28][29][30], fluorescence [31][32][33][34][35][36][37][38][39] or electrochemical [40][41][42] detection. However, these detection methods have limited sensitivity and specificity.…”

Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK

“…An excellent example from the work of the Phase I/II Committee relates to the Phase I trial of an antagonist of mitogenic neuropeptide growth factors, substance P antagonist G (IV -SPAG, Cummings et al, 1999;Clive et al, 2001). In this study, forearm blood flow/venous plethysmography was used to show that SPAG levels could be achieved in patients, which blocked substance P-induced vasodilation.…”